GlaxoSmithKline: Diabetes Mellitus, Type 2 trials
The registry lists 136 Diabetes Mellitus, Type 2 studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 46 have results posted.
Phase 1 51Phase 2 23Phase 3 29Phase 4 23No phase 11(a study in two phases counts in both)
Studies
Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus SubjectsTerminatedNCT02793154Phase 4Results posted
- Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus SubjectsTerminatedNCT02750930Phase 4Results posted
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes MellitusCompletedNCT02683746Phase 3Results posted
- A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy SubjectsCompletedNCT02496221Phase 4Results posted
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusCompletedNCT02465515Phase 4Results posted
- Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes MellitusCompletedNCT02229227Phase 3Results posted
- A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With GastroparesisCompletedNCT02210000Phase 2Results posted
- A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes PatientsCompletedNCT02202161Phase 2Results posted
- Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking MetforminCompletedNCT01929863Phase 2Results posted
- OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.CompletedNCT01842620Phase 4Results posted
- An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II DiabetesTerminatedNCT01817777Phase 4Results posted
- A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT01733758Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes MellitusCompletedNCT01627340Phase 4Results posted
- Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian VolunteersCompletedNCT01561976Not applicableResults posted
- Albiglutide Glucose Clamp Study in Subjects With Type 2 DiabetesCompletedNCT01475734Phase 2Results posted
- An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes PatientsTerminatedNCT01453049Phase 3Results posted
- A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With MetforminCompletedNCT01376323Phase 2Results posted
- Pharmacokinetics/Pharmacodynamics of AlbiglutideCompletedNCT01357889Phase 2Results posted
- Avandamet Bioequivalence Study Brazil - Fed AdministrationCompletedNCT01332071Phase 1Results posted
- An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010CompletedNCT01294553Results posted
- A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.CompletedNCT01128894Phase 3Results posted
- A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263CompletedNCT01128621Phase 2Results posted
- A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and PharmacodynamicsCompletedNCT01119846Phase 2Results posted
- A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.CompletedNCT01098539Phase 3Results posted
- Dose Ranging Study of Albiglutide in Japanese SubjectsCompletedNCT01098461Phase 2Results posted
- Fracture Risk With ThiazolidinedionesCompletedNCT01055223Results posted
- A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineCompletedNCT00976391Phase 3Results posted
- Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human SubjectsCompletedNCT00937326Phase 2Results posted
- Thiazolidinedione Intervention With Vitamin D EvaluationTerminatedNCT00879970Phase 4Results posted
- Safety and Efficacy of Albiglutide in Type 2 DiabetesCompletedNCT00849056Phase 3Results posted
- Safety and Efficacy Study of Albiglutide in Type 2 DiabetesCompletedNCT00849017Phase 3Results posted
- A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 DiabetesCompletedNCT00839527Phase 3Results posted
- A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesCompletedNCT00838916Phase 3Results posted
- Efficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesCompletedNCT00838903Phase 3Results posted
- Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone HealthCompletedNCT00679939Phase 4Results posted
- Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin OnlyCompletedNCT00518115Phase 2Results posted
- Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)CompletedNCT00500331Phase 2Results posted
- Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-NaiveCompletedNCT00495469Phase 2Results posted
- A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo StudyCompletedNCT00432679Phase 3Results posted
- A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. MetforminCompletedNCT00386100Phase 4Results posted
- RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesCompletedNCT00379769Phase 3Results posted
- Study Of GW823093 In Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT00372957Phase 2Results posted
- Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 DiabetesCompletedNCT00367055Phase 4Results posted
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 DiabetesCompletedNCT00318656Phase 4Results posted
- A Study In Patients With Type 2 Diabetes MellitusCompletedNCT00256867Phase 3Results posted
- A New Oral Treatment For Type II Diabetes MellitusCompletedNCT00111800Phase 2Results posted
- A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes MellitusWithdrawnNCT03015519Phase 3
- Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult SubjectsCompletedNCT02660736Phase 1
- Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes MellitusWithdrawnNCT02229240Phase 3
- Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02058641Phase 1
- Glucagon-like Peptide (GLP) Utilization and SafetyCompletedNCT01767389
- Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health VolunteersTerminatedNCT01725672Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.CompletedNCT01607385Phase 1
- Type II Diabetes Mellitus in Patients Exposed to Pravastatin and ParoxetineCompletedNCT01602913
- A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes MellitusCompletedNCT01571661Phase 1
- A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy VolunteersCompletedNCT01545570Phase 1
- A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes MellitusCompletedNCT01495013Phase 3
- First Time in Human Study Using GSK2330672CompletedNCT01416324Phase 1
- Albiglutide Thorough ECG Study in Healthy VolunteersCompletedNCT01406262Phase 1
- Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in LatinaCompletedNCT01387165
- Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 DiabeticsCompletedNCT01357876Phase 1
- A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic DiseasesCompletedNCT01340911Phase 1
- Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs RosiglitazoneCompletedNCT01332370
- Malignancy Meta Analysis for BRL49653CompletedNCT01195259
- Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in KoreaCompletedNCT01154244
- A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 DiabeticsCompletedNCT01147861Phase 1
- A Drug Interaction Study With Albiglutide and WarfarinCompletedNCT01147731Phase 1
- A Drug Interaction Study of Albiglutide and DigoxinCompletedNCT01147718Phase 1
- A Drug Interaction Study of Simvastatin and AlbiglutideCompletedNCT01147692Phase 1
- A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy SubjectsCompletedNCT01101568Phase 1
- An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .CompletedNCT01077505Phase 1
- Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes MellitusCompletedNCT01045590Phase 4
- A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes MellitusCompletedNCT01031108Phase 1
- A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male VolunteersCompletedNCT01018628Phase 1
- A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes MellitusCompletedNCT01018017Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 DiabeticsCompletedNCT01013766Phase 1
- Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UKCompletedNCT00995995
- A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 DiabetesCompletedNCT00976261Phase 1
- A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy VolunteersCompletedNCT00938275Phase 1
- A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.CompletedNCT00938158Phase 1
- A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male SubjectsCompletedNCT00937872Phase 1
- A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male VolunteersCompletedNCT00933530Phase 1
- Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male VolunteersCompletedNCT00933062Phase 1
- A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal SubjectsCompletedNCT00823940Phase 1
- A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.CompletedNCT00733577Phase 1
- A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II DiabetesCompletedNCT00675857Phase 2
- A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or HydrochlorothiazideCompletedNCT00671424Phase 1
- Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes SubjectsCompletedNCT00648284
- A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male SubjectsCompletedNCT00625859Phase 1
- Effect of GSK376501 on CYP450 Activity in Healthy Adult SubjectsCompletedNCT00615212Phase 1
- First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050CompletedNCT00607906Phase 1
- A Drug Interaction Study Between Simvastatin and GSK376501CompletedNCT00605449Phase 1
- A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy SubjectsCompletedNCT00559884Phase 1
- Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone MaleateCompletedNCT00551564Phase 1
- Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.CompletedNCT00537719Phase 1
- A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy AdultsCompletedNCT00532610Phase 1
- Clinical Assessment of GSK716155 for Type 2 Diabetes MellitusCompletedNCT00530309Phase 1
- A Study Of BRL49653C For The Treatment Of Type 2 DiabetesCompletedNCT00523913Phase 3
- A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of MetforminCompletedNCT00519480Phase 1
- A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female VolunteersCompletedNCT00504816Phase 1